Physician profile
Stephen L Herr
NPI 1326005091
$2,536.77
in general payments reported to CMS, 2019-2025
17 companies · $101 in 2025
The $101 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $479 · 2020: $523 · 2022: $169 · 2023: $277 · 2024: $987 · 2025: $101.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,280 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,279.96 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $681.20 | 2019-2025 | |
| Janssen Biotech, INC. | $635.07 | 2019-2025 | Stelara, Tremfya, Simponi |
| Ironwood Pharmaceuticals, INC | $157.92 | 2019-2024 | Linzess |
| Phathom Pharmaceuticals, INC. | $155.63 | 2024 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $126.05 | 2024 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $122.11 | 2024 | Zeposia |
| Pfizer INC. | $119.22 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $119.13 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $108.32 | 2020-2024 | Xifaxan |
| Gilead Sciences, INC. | $104.13 | 2019-2020 | |
| Intercept Pharmaceuticals, INC. | $61.29 | 2019-2020 | |
| Allergan, INC. | $57.24 | 2019 | |
| Merck Sharp & Dohme LLC | $22.63 | 2024 | Dificid |
| Evoke Pharma, INC. | $22.48 | 2023 | Gimoti |
| Celgene Corporation | $16.22 | 2023 | Zeposia |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $14.70 | 2019 | |
| Endo Pharmaceuticals INC. | $13.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Herr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.